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Abstract 
Background: In vitro drug susceptibility testing of malaria parasites remains an important component of surveil-
lance for anti-malarial drug resistance. The half-maximal inhibition of growth (IC50) is the most commonly reported 
parameter expressing drug susceptibility, derived by a variety of statistical approaches, each with its own advantages 
and disadvantages.
Methods: In this study, licensed computer programs WinNonlin and GraphPad Prism 6.0, and the open access pro-
grams HN-NonLin, Antimalarial ICEstimator (ICE), and In Vitro Analysis and Reporting Tool (IVART) were tested for their 
ease of use and ability to estimate reliable IC50 values from raw drug response data from 31 Plasmodium falciparum 
and 29 P. vivax clinical isolates tested with five anti-malarial agents: chloroquine, amodiaquine, piperaquine, meflo-
quine, and artesunate.
Results: The IC50 and slope estimates were similar across all statistical packages for all drugs tested in both spe-
cies. There was good correlation of results derived from alternative statistical programs and non-linear mixed-effects 
modelling (NONMEM) which models all isolate data simultaneously. The user-friendliness varied between packages. 
While HN-NonLin and IVART allow users to enter the data in 96-well format, IVART and GraphPad Prism 6.0 are capable 
to analyse multiple isolates and drugs in parallel. WinNonlin, GraphPad Prism 6.0, IVART, and ICE provide alerts for 
non-fitting data and incorrect data entry, facilitating data interpretation. Data analysis using WinNonlin or ICE took the 
longest computationally, whilst the offline ability of GraphPad Prism 6.0 to analyse multiple isolates and drugs simul-
taneously made it the fastest among the programs tested.
Conclusion: IC50 estimates obtained from the programs tested were comparable. In view of processing time and 
ease of analysis, GraphPad Prism 6.0 or IVART are best suited for routine and large-scale drug susceptibility testing.
© 2016 Wirjanata et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria remains a serious public health problem in 
endemic countries [1]. Efforts to control and eliminate 
malaria have failed repeatedly, often due to the spread 
of drug-resistant parasites and vectors. Resistance has 
emerged and spread to all currently available anti-malar-
ials and reinforces the need for better surveillance strat-
egies. In vitro assays for assessing anti-malarial drug 
susceptibility are an important part of monitoring drug 
resistance and investigation of novel anti-malarial com-
pounds [2]. Although artemisinin-based combination 
therapy (ACT) has been implemented widely for the 
treatment of falciparum malaria and has proven to be 
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beneficial, it is important to consider that resistance to 
one component of the therapy can be masked by a part-
ner drug which retains high anti-malarial efficacy. In vitro 
assays also provide an opportunity to assess drug suscep-
tibility of parasites to individual drugs, thereby allowing 
preventive measures to be taken before clinical treat-
ment failure occurs. In addition, in vitro assays enable the 
measurement of drug sensitivity without the confound-
ing effects of clinical efficacy such as host immunity and 
the pharmacokinetics of the drug [2–4].
A variety of assays are available to measure drug sus-
ceptibility in Plasmodium falciparum. In most, the para-
sites’ drug susceptibility is defined by measuring growth 
(i.e., schizont maturation) or replication (i.e., re-invasion 
assays) in the presence of varying concentrations of anti-
malarial compounds. Although these assays are highly 
informative, the comparison of data between laboratories 
or field sites is often problematic as numerous variations 
exist between protocols, such as the initial parasitaemia, 
incubation time, culture haematocrit, and the use of 
alternative media and supplements [5, 6].
Standard analysis of in  vitro (culture-adapted Plas-
modium strains) and ex vivo (fresh Plasmodium clinical 
isolates) assay data is commonly conducted by using non-
linear regression to fit a sigmoid Emax model to each sam-
ple’s concentration-effect data. The sigmoid Emax model 
is comprised of four parameters: minimum and maxi-
mum effects, steepness (=slope) of the dose–response 
curve, and concentration of the drug required to inhibit 
growth to 50  % of that observed in the absence of the 
drug (IC50). In this approach, the definition of IC50 is 
based on the assumptions that there is: (a) a monotonic 
relationship between the dose of the compound tested 
and the response in the assay; and, (b) a consistent 50 % 
response can be defined clearly [7]. IC50 values can also 
be estimated using alternative statistical models, such as 
polynomial regression [8] and sigmoid inhibition models 
based on non-linear regression [9, 10]. Determination of 
reproducible IC50 values remains a challenge for inves-
tigators as it is time-consuming and often subjective as 
the process itself involves visual inspection of individual 
dose–response curves [10]. Moreover, laboratories have 
different criteria for accepting or rejecting assay data, 
leading to a variety of selection biases, such as excluding 
assays from highly resistant parasites for which IC50 esti-
mates tend to be less precise [11].
Different computer programs and online platforms are 
available, each with its own algorithms and features, to 
facilitate the processing of raw drug assay data. In this 
study, five of the most commonly used analytical plat-
forms were assessed by applying them to the same data-
set of ex vivo drug response data collected from patients 
with clinical malaria and comparing the derived output 




From April 2012 to January 2013, Plasmodium spe-
cies isolates were collected from patients with malaria 
attending an outpatient clinic in Timika, Papua Prov-
ince, Indonesia. In this region, clinical trials have con-
firmed high levels of multidrug-resistant P. vivax and P. 
falciparum [12–14]. Patients with symptomatic malaria 
were recruited into the study if they had a single species 
infection with P. falciparum or P. vivax, with a parasi-
taemia of between 2000 and 80,000 μL−1 as determined 
by microscopy, and with synchronous infection with at 
least 70 % parasites at ring stage. Patients were excluded 
from the study if they had taken any anti-malarials in 
the preceding month. After written informed consent 
was obtained, 5 mL venous blood was collected by veni-
puncture. Host white blood cells (WBC) were removed 
using cellulose column filtration and packed infected red 
blood cells (IRBC) used for the ex vivo drug susceptibil-
ity assay.
Ex vivo drug susceptibility assay
Plasmodium drug susceptibility was measured using a 
protocol modified from the World Health Organization 
(WHO) microtest as described previously [12, 15]. Two-
hundred microlitres of a 2 % haematocrit blood medium 
mixture (BMM), consisting of RPMI 1640 medium plus 
10 % AB+ human serum (P. falciparum) or McCoy’s 5A 
medium plus 20  % AB+  human serum (P. vivax) were 
added to each well of pre-dosed drug plates containing 
11 serial concentrations (twofold dilutions) of the anti-
malarials (maximum concentration shown in paren-
theses) chloroquine (2992  nM), piperaquine (769  nM), 
mefloquine (338  nM), artesunate (49  nM), and amo-
diaquine (158  nM). Pre-dosed drug plates were made 
by diluting the compounds in 50  % methanol, followed 
by lyophilization, and stored at 4  °C until use. All anti-
malarials were obtained from the World Wide Antima-
larial Resistance Network (WWARN) Malaria Drug 
Reference Material Scheme [16].
Dose–response analysis
The raw dose–response data for each drug were visually 
checked to ensure that they were amenable to regres-
sion modelling. Five programs and/or online tools were 
evaluated.
WinNonlin 4.1 (Pharsight Corporation)
IC50 values were estimated using the program WinNon-
lin 4.1 (Pharsight Corp) by fitting a sigmoid Emax model 
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(Eq.  1) to each individual isolate’s concentration-effect 
data by non-linear regression
E represents the percentage of schizonts observed after 
normalization to the control wells using the following 
equation:
Eraw is the percentage of schizont observed in the drug 
well and divided by the percentage of schizont observed 
in the control well (Econtrol). Maximum inhibition occurs 
when there is no observable schizont (i.e., inhibition of 
growth), that is, E equals 0. In Eq. 1, E0 represents mini-
mum per cent growth, Emax maximum per cent growth, 
IC50 the concentration of the drug required to inhibit 
50 % of the control parasites’ schizont growth, C the drug 
concentration, and γ the steepness of the curve (slope).
Initial raw data were transposed into an Excel con-
verter worksheet to fulfil the program’s template require-
ments. The converted data were then transposed into 
the program’s data table and analysed using the phar-
macodynamic inhibitory sigmoid Emax model presented 
above (see Eq.  1). Key outputs and additional param-
eters are presented in Table  3. Warning messages were 
shown when potential inaccuracies were identified, such 
as steep response without observed values on the slope, 
and dose–response curves were provided for visual 
inspection.
Isolates with estimated Emax and E0 values above 15 % 
or below 100 and 0, respectively, were re-analysed. The 
majority of these results were caused by either resistant 
isolates in which the response was deemed inadequate 
at the highest drug concentration tested, or lower schiz-
ont counts at the lowest concentration tested than those 
of untreated controls. In such cases, additional extreme 
data points were added assuming E = 1 with no drug and 
0 when very high drug concentrations were present.
GraphPad Prism (version 6.01; GraphPad Software, Inc.)
Dose–response analysis of the log-transformed drug 
concentrations (represented by X in Eq. 2) and response 
(represented by Y in Eq. 2) was performed using the ‘log 
(inhibitor) versus response–variable slope’ equation (Hill 
equation):
Bottom represents the value of Y for the minimal curve 
asymptote (response in the absence of drug), Top is the 




















value of Y for the maximal curve asymptote (response 
produced by an infinitely high concentration of drug). 
LogIC50 is the logarithm of the drug concentration 
required to inhibit 50  % of growth, and γ represent the 
slope of the curve. The upper and lower limits of γ were 
constrained to 10 and 0, respectively.
Raw data were first transferred into an Excel converter 
worksheet to fulfil the program’s template requirements. 
The converted raw data were then transposed into the 
program’s Y-axis data table and the drug concentrations 
entered into the X-axis data table; the data were log-
transformed prior to analysis. In GraphPad Prism 6.0, the 
results were available immediately after data entry. Key 
and additional outputs are outlined in Table  3. Dose–
response curves were also produced for visual inspection. 
The program showed ‘ambiguous’ text warnings when it 
was unable to find the combination of parameters that 
best fit the data. A warning text was shown for the fol-
lowing reasons: (i) data were not collected over a wide 
enough range of drug concentrations; (ii) the model 
had redundant parameters (i.e., the model could be fit-
ted with multiple sets of parameters); or, (iii) the model 
resulted in a biphasic curve, leading to different IC50 val-
ues [17]. In the case of ‘ambiguous’ results due to reason 
(i), additional extreme data points were added, assuming 
Y equals to 0 when very high drug concentrations were 
present, and data were re-analysed.
HN‑NonLin
HN-NonLin is a freeware program [18] that uses log-
transformed data to fit a polynomial regression model 
with the following equation (Eq. 3):
The goal of polynomial regression is to find the values 
of the parameters A, B, C, etc., that are going to gener-
ate the best-fit curve for the observed data points. When 
using a polynomial regression model, investigators need 
to specify the order of the polynomial (i.e., the numbers 
of parameters to be fitted into the equation) [19]. In 
HN-NonLin, users can choose the order of the polyno-
mial (i.e., 1–7) that will determine the shape of the dose–
response curve: Polynomial ‘1’ will give a straight line, 
while polynomial ‘7’ will produce a perfect interpolation 
(i.e., the regression line will pass through all data points). 
In this study, polynomial ‘3’ was chosen since polynomi-
als at higher order will produce perfect correlation, but 
undesirable oscillations caused by outliers [20].
To conduct data modelling using HN-NonLin, raw data 
were transferred into an Excel converter worksheet in 
order to fit the 96-well plate format of the program. After 
the polynomial was set, data modelling was performed 
and the key parameters, as well as additional outputs 
(3)Y = A+ Bx + Cx2 + Dx3 + Ex4
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generated as presented in Table  3. As with the other 
programs, additional extreme data points were added 
in cases where drug-response data were deemed inad-
equate, assuming that no schizont was observed at very 
high drug concentrations.
ICEstimator 1.2
The ICEstimator is a freeware online program that car-
ries out a non-linear regression on the relative concen-
tration-effect points by using an inhibitory sigmoid Emax 
model [9].
Raw data were transferred into an Excel converter 
worksheet to comply with the program’s requirements. 
Converted raw data were then entered via the ICEstima-
tor 1.2 website [21]. For the analysis of each isolate, drug 
concentration (x-axis) and response data (y-axis) needed 
to be entered individually. In the current study, the 
unit for concentration was set to ‘nM’ and for response 
‘other’ was chosen. In addition, ‘schizont counting’ was 
chosen as the method for analysis. Data modelling was 
performed online generating the outputs outlined in 
Table  3. Dose–response curves were available for indi-
vidual inspection. Warning signs were displayed if: (i) 
the ratio of the upper and lower limits of the 95  % CI 
of the IC50 was greater than two; (ii) convergence was 
unsuccessful, even when the slope was set at 10; (iii) the 
parasite’s growth ratio (mean effect at drug-free control/
mean effect at maximum drug concentration) was less 
than two; (iv) the lower limit of the IC50 95 % CI was less 
than 0; and/or, (v) IC99> maximum concentration [9]. The 
results, as well as dose–response curves were displayed 
directly on the website and were available for download 
in portable data file (pdf ) and comma-separated value 
(csv) format.
In Vitro Analysis and Reporting Tool (IVART)
IVART is a freeware online program that was developed 
by WWARN. IVART is a program that is based on the 
code of the ICEstimator program and described in detail 
on the WWARN website [10].
Raw data were transferred into an Excel converter 
worksheet and converted into a 96-well format to com-
ply with the program’s requirements. Converted raw data 
were then entered into the WWARN pre-build Excel 
worksheet as per the developer’s instructions [22]. This 
worksheet was then uploaded through the WWARN 
website [23] and data analysis performed online. The 
results took approximately 1 min to be generated follow-
ing data upload and could be downloaded as pdf and/
or csv files. Key and additional outputs are outlined in 
Table 3. In the pdf output, warning messages were shown 
when (a) drug concentration ranges were incorrect; or, 
(b) core criteria, as described elsewhere [10], were not 
met. If warning signs were shown, additional drug con-
centrations and data points were added as described 
above and the data re-analysed.
Non‑linear mixed‑effects modelling using the package 
NONMEM
The estimates obtained by all the programs tested were 
compared with the estimates produced by NONMEM. 
NONMEM is a commercial software package that anal-
yses data from all isolates simultaneously using non-
linear mixed-effects models to take into account the 
two sources of variability, within- and between-isolate 
variability. NONMEM allows the specification of any 
non-linear regression equation to describe the effect-
concentration curves and can incorporate other con-
founding factors of the drug assay, such as parasite stage 
composition at the start of the assay, assay duration, and 
the use of different drug plate batches. For this analysis, 
the sigmoid Emax model (i.e., Eq. 1) was used and no addi-
tional confounding factors were included. The derivation 
of IC50 values using NONMEM is described in detail 
elsewhere [24].
Data analysis
Results from each program were pooled and statistical 
analysis conducted using GraphPad Prism 6.0. Geometric 
mean and 95 % reference range of IC50 and slope parame-
ters were calculated for each drug using all available pro-
grams. NONMEM was used as the reference method and 
parameter estimates compared with each of the other 
methods. Bland–Altman plots using the derived IC50 
estimates were created to compare agreement between 
programs.
In addition, a qualitative analysis was conducted to 
assess the ease of use and application of each method-
ology. This included how the raw data were processed, 
data conversion and/or transformation, data upload, data 
analysis, processing time, capability to perform batch 
analysis, capability of offline analysis, and costs.
Ethical approval
Ethical approval for this project was obtained from the 
Human Research Ethics Committee of the Northern Ter-
ritory Department of Health and Families and Menzies 
School of Health Research (HREC 2010–1396), Darwin, 
Australia, and the Eijkman Institute Research Ethics 
Commission (EIREC-47), Jakarta, Indonesia.
Results
Overview and comparison of outputs
Ex vivo drug susceptibility assays to chloroquine, amo-
diaquine, piperaquine, mefloquine, and artesunate were 
assessed in field isolates from 60 patients presenting with 
Page 5 of 10Wirjanata et al. Malar J  (2016) 15:137 
single-species infections of P. falciparum (n  =  31) and 
P. vivax (n = 29). Drug susceptibility data were success-
fully derived from all samples. Baseline characteristics of 
the isolates processed are presented in Table  1 and the 
derived drug susceptibility for both species depicted in 
Fig. 1. The population geometric mean IC50s were similar 
for the five different methodologies with no significant 
differences when compared to the NONMEM reference 
estimates (see Tables 2 and 4). With the exception of HN-
NonLin, all programs generated estimates of the slope (γ) 
and corresponding 95 % confidence intervals (Table 3).
For resistant isolates, both the IC50 and the shape of 
the dose response curve shift, and hence both param-
eters, are required to calculate the inhibitory responses 
at other concentrations, such as the IC90 or IC99. All pro-
grams produced dose–response curves for visual inspec-
tion, but only WinNonlin, GraphPad Prism 6.0, and 
HN-NonLin generated statistics for the goodness of fit 
of the final model. Although this statistic is not shown in 
ICE and IVART, warning messages are displayed when 
the regression fails to produce an acceptable fit.
Visual inspection of both raw data and dose-response 
curves is inevitable for final interpretation of IC50 esti-
mates. When data cannot be modelled for reasons such 
as similar schizont growth at each drug concentration 
compared to the drug-free control, or non-sigmoidal 
curves, none of the software packages generated IC50 
values or drug response curves. In these cases, ICE, 
IVART and WinNonlin also displayed error messages. 
For assays with a large discrepancy of response between 
duplicate concentrations on the slope, GraphPad Prism 
6.0 and WinNonlin tended to produce higher IC50 esti-
mates and lower slope values compared to the other 
packages. This shift in IC50s was most prominent when 
Table 1 Baseline characteristics of isolates used for analysis
CI, confidence interval
Baseline characteristic P. falciparum (n = 31) P. vivax (n = 29)
Median (range) delay from venipuncture to start of culture (minutes) 116 (80–180) 131 (75–210)
Median (range) duration of assay (hours) 45 (42–50) 46 (32–50)
Geometric mean (95 % CI) parasitaemia (asexual parasites/μL) 11,832 (9282–15,084) 17,233 (11,902–24,952)
Median initial % (range) of parasites at ring stage 100 (100–100) 95 (70–99)
Mean (95 % CI) schizont count at harvest 43 (36–49) 44 (40–47)
Fig. 1 Ex vivo drug susceptibility (median IC50s) of standard anti-malarials in Plasmodium falciparum (closed symbols) and Plasmodium vivax (open 
symbols) clinical field isolates. IC50 estimates depicted in the Figure were derived by using NONMEM
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one of duplicates was zero on the slope (i.e., GraphPad 
Prism 6.0 and WinNonlin automatically excluded the 
zero value as outlier).
The IVART, as described by Woodrow and colleagues 
[10], was designed primarily for ≥48  h in  vitro re-inva-
sion assays, rather than the schizont maturation assay 
used in the current analysis. IVART generates a growth 
ratio, defined as the uninhibited growth divided by maxi-
mally inhibited growth. In the schizont maturation assay, 
maximum inhibition leads to zero schizont count, thus 
producing infinite values at these concentrations [10]. 
Nevertheless, IVART could still be successfully applied 
to the schizont maturation data, producing similar esti-
mates as the other programs.
Agreement with NONMEM
Bland–Altman plots were produced to measure the 
agreement between the different programs and NON-
MEM for every anti-malarial according to the species of 
infection. Overall, there was good concordance between 
all programs and NONMEM. The biases (mean dif-
ferences in estimates) were close to zero for all drugs 
assessed (range 3.80–1.76  nM; Additional files 1, 2, 3, 
4 and 5). In total, 80 out of 1485 (5.4 %) assays had dif-
ferences outside the 95  % limits of agreement of the 
mean difference and were termed outliers. The major-
ity of these outliers (30/80, 37.5  %) were derived from 
assays with a large discrepancy in duplicate microscopy 
readings, possibly caused by human error, leading to 
Table 2 Comparison of IC50 values for concentration-effect curves of anti-malarial drugs against Plasmodium falciparum 
and Plasmodium vivax generated by different programs
a Median difference (range) for each method compared with NONMEM (values in italics) used as the reference method for comparison
P. falciparum P. vivax




Method Geometric mean 





NONMEM 91.40 (74.39–108.40) Chloroquine 
(n = 29)
NONMEM 151.9 (124.2–179.6)
GP 81.43 (67.67–98.00) 0.42 (−7.80 to 6.50) GP 137.8 (115.8–163.9) 0.37 (−50.0-32.0)
HNL 81.59 (67.26–98.97) 0.42 (−5.50 to 13.0) HNL 136.7 (114.3–163.5) 0.33 (−47.0 to 35.0)
ICE 82.59 (68.45–99.65) 1.50 (−5.00 to 11.0) ICE 137.4 (115.7–163.2) 1.80 (−62.0 to 10.0)
IVART 83.85 (69.20–101.6) 0.93 (−12.0 to 40.0) IVART 135.2 (113.0–161.7) 1.90 (−62.0 to 17.0)
WNL 81.40 (67.62–98.00) 0.51 (−5.40 to 5.10) WNL 136.4 (114.7–162.1) 0.18 (−63.0 to 12.0)
Piperaquine 
(n = 31)
NONMEM 25.65 (20.79–30.50) Piperaquine 
(n = 28)
NONMEM 26.03 (18.99–33.08)
GP 21.77 (17.79–26.64) 0.56 (−9.60 to 3.30) GP 20.46 (15.51–26.99) −0.08 (−3.80 to 2.30)
HNL 22.35 (18.30–27.30) −0.22 (−5.10 to 13.0) HNL 21.26 (16.21–27.89) 0.68 (−4.80 to 6.90)
ICE 22.72 (18.44–27.99) 0.44 (−3.00 to 4.90) ICE 20.99 (15.99–27.54) 0.14 (−1.70 to 3.10)
IVART 22.10 (17.88–27.32) −0.02 (−11.0 to 4.90) IVART 21.34 (16.35–27.85) 0.24 (−2.20 to 3.80)
WNL 21.93 (17.92–26.85) −0.28 (−9.20 to 3.30) WNL 20.64 (15.68–27.18) −0.05 (−1.80 to 1.70)
Mefloquine 
(n = 31)
NONMEM 13.49 (10.26–16.71) Mefloquine 
(n = 29)
NONMEM 21.67 (15.23–28.11)
GP 10.99 (8.55–14.11) 0.01 (−1.30 to 2.90) GP 16.53 (12.12–22.56) 0.27 (−0.81 to 4.40)
HNL 11.31 (8.85–14.45) 0.24 (−0.89 to 3.80) HNL 16.61 (12.24–22.54) 0.26 (−2.30 to 3.40)
ICE 11.31 (8.84–14.46) 0.38 (−0.15 to 2.80) ICE 16.82 (12.38–22.87) 0.56 (−0.32 to 3.20)
IVART 10.59 (8.14–13.76) 0.03 (−5.10 to 3.10) IVART 16.61 (12.00–23.00) 0.51 (−2.50 to 5.40)
WNL 11.04 (8.59–14.17) 0.03 (−0.82 to 2.30) WNL 16,341 (12.01–22.43) 0.12 (−1.20 to 3.00)
Amodiaquine 
(n = 30)
NONMEM 14.53 (12.18–16.88) Amodiaquine 
(n = 28)
NONMEM 24.97 (20.29–29.64)
GP 13.40 (11.21–16.03) −0.05 (−2.70 to 11.0) GP 22.03 (17.4–27.80) 0.04 (−3.60 to 8.00)
HNL 13.59 (11.42–16.18) 0.46 (−2.80 to 2.60) HNL 22.31 (17.66–28.18) 1.10 (−2.10 to 4.50)
ICE 13.24 (11.16–15.71) 0.04 (−1.10 to 0.87) ICE 21.74 (17.34–27.25) 0.07 (−1.80 to 0.81)
IVART 13.24 (11.16–15.71) 0.04 (−1.10 to 0.87) IVART 21.88 (17.31–27.10) −0.03 (−1.80 to 0.81)
WNL 13.38 (11.22–15.96) −0.04 (−1.30 to 11.0) WNL 21.88 (17.36–27.57) −0.02 (−2.20 to 4.30)
Artesunate 
(n = 31)
NONMEM 5.43 (3.23–7.63) Artesunate 
(n = 28)
NONMEM 4.12 (2.38 to 5.85)
GP 3.59 (2.48–5.19) 0.01 (−0.14 to 1.10) GP 2.47 (1.63–3.75) 0.01 (−0.64 to 0.82)
HNL 3.57 (2.52–5.07) −0.01 (−2.60 to 11.0) HNL 2.55 (1.69–3.85) 0.06 (−0.73 to 2.60)
ICE 3.51 (2.48–4.67) 0.05 (−0.14 to 0.99) ICE 2.50 (1.65–3.79) 0.04 (−0.30 to 0.79)
IVART 3.54 (2.54–4.94) 0.07 (−2.90 to 0.84) IVART 2.45 (1.61–3.72) 0.01 (−0.63 to 0.43)
WNL 3.61 (2.49–5.23) 0.01 (−0.40 to 10.0) WNL 2.48 (1.63–3.76) 0.01 (−0.41 to 1.00)
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responses with biphasic curves [9, 25]. In these outli-
ers, the difference in IC50 values with the NONMEM 
value was higher in GraphPad Prism 6.0 compared to 
other methods. Data with a very steep slope (i.e., slope 
estimate  =  10) accounted for 30  % (24/80) of outliers. 
For all these outliers, NONMEM consistently produced 
lower slope values compared to other methods, ranging 
from 2.9 to 4.9 (Table 4). For the assays with steep slopes, 
GraphPad Prism 6.0, IVART and ICE tended to produce 
higher IC50 estimates than NONMEM. In total, 23.8  % 
(19/80) of the outliers had parasite growth at the high-
est concentration of the drug tested (i.e., 100 % inhibition 
was never reached). Whereas NONMEM interpreted 
these data within the context of the whole population, for 
the other programs, Emin was anchored to zero, assum-
ing zero growth was eventually reached with very high 
drug concentrations. However, this approach needs to be 
interpreted with caution. Data with ‘plateau responses’ 
(i.e., the same schizont counts were recorded for two 
or more different drug concentrations before it reached 
the maximum effect) were present in 5  % (4/80) assay 
outliers. The rest of the outliers (3.7 %; 3/80) were gener-
ated by IVART where a very wide confidence interval for 
the IC50 values was generated.
Qualitative analysis
The key features of each package are summarized in 
Table 3.
Data conversion and transformation
All of the programs had individual template requirements. 
To fulfil these, raw data were converted into an Excel file 
first before transposing into the appropriate template. 
This process was critical and error-prone for WinNonlin, 
ICE and GraphPad Prism 6.0, where raw data needed to 
be entered manually in either row or column format. Data 
conversion for HN-NonLin and IVART was easier, since 
the data could be transferred in a 96-well format, reduc-
ing the risk for transcription errors. The in  vitro assay 
relies on a process of normalizing the response at each 
concentration against a control well with no drug expo-
sure. With the exception of WinNonlin, the normalization 
Table 3 Key outputs and features of the different analysis tools
a Based on the capability to enter the data in 96-well format
b Based on the capability to run one isolate with five different drugs in duplicates distributed on two different 96-well plates
c Time measurement includes the time needed to transfer raw data into a ‘converter’ spreadsheet and double checking the converted data to ensure that raw data 
was correctly entered and converted
d Time measurement includes the time needed to transfer the converted raw data into the corresponding programs until the outputs were successfully transferred 
into a separate analysis spreadsheet
e For NONMEM, data from all isolates are modelled simultaneously
Method






 Free ✔ ✔ ✔
 96-well formata ✔ ✔
 Batch analysis of multiple drugs ✔ ✔ ✔ ✔
 Batch analysis of multiple isolates ✔e ✔ ✔ ✔
 Offline processing ✔ ✔ ✔
Key output
 IC50 estimate ✔ ✔ ✔ ✔ ✔ ✔
 Slope estimate ✔ ✔ ✔ ✔ ✔
 Confidence interval of estimates ✔ ✔ ✔ ✔ ✔
 Success criteria and warning signs ✔ ✔ ✔ ✔
 Dose–response curve ✔ ✔ ✔ ✔ ✔
Data processing and analysis
 Data conversion Critical Critical Easy Critical Easy
 Approximate time needed for data conversion (seconds)b, c 45 25 25 25 25
 Data upload/entry Critical Critical Easy Critical Easy
 Approximate time needed for data upload and processing 
(seconds)b, d
120 15 20 300 90
 Approximate total time needed to obtain estimates (seconds) 165 40 45 325 115
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algorithm is included in the analysis for all the statistical 
packages assessed in this study.
Plate format and templates
Drug susceptibility assays generally use drug plates in a 
96-well format. Although the eight-well rows of a 96-well 
plate are sufficient to generate valid dose–response 
curves and IC50 estimates [4], most investigators prefer 
to use the 12-well columns of a 96-well plate in order to 
have a broader drug concentration range. In WinNon-
lin, GraphPad Prism 6.0, HN-NonLin, and IVART, users 
can enter pre-made drug concentration templates prior 
to processing, without the need to reset the template for 
every single analysis. This feature also allows the analy-
sis of multiple drugs for the same isolate. This is not pos-
sible with ICE, which requires the drug concentration 
and response to be entered manually for each drug per 
isolate.
The number of drugs that can be assessed also var-
ies. GraphPad Prism 6.0 allows the user to enter a user-
defined number of drug concentrations as long the 
drug concentrations entered into the program are log-
transformed. The drug template in HN-NonLin allows a 
maximum of 12 different drugs with seven different con-
centrations and one control well in a 96-well format. In 
IVART, the layout is more flexible and allows testing of 
eight to 12 different drugs with seven different concen-
trations plus one control well per drug, or 11 different 
concentrations and one control well per drug. Different 
96-well plate templates employed by these programs can 
be suited to accommodate the investigator’s needs. With 
horizontal drug dilutions, investigators are able to obtain 
more data points and a wider dynamic range with a spe-
cific drug; this is particularly useful when testing novel 
anti-malarials with unknown IC50s. With vertical dilu-
tions, investigators are able to test more anti-malarials 
Table 4 Comparison of  slope values for  concentration-effect curves of  anti-malarial drugs against  Plasmodium falcipa-
rum and Plasmodium vivax
a Median difference (range) for each method compared with NONMEM (values in italics) used as the reference method for comparison
P. falciparum P. vivax










NONMEM 3.09 (2.72–3.46) Chloroquine 
(n = 29)
NONMEM 3.86 (2.99–4.72)
GP 3.15 (2.66–3.73) 0.03 (−0.20 to 4.85) GP 3.48 (2.75–4.39) 0.06 (−0.46 to 2.82)
ICE 3.33 (2.84–3.91) 0.17 (0.03 to 4.85) ICE 3.67 (2.93–4.60) 0.20 (−0.46 to 2.82)
IVART 3.40 (2.91–3.97) 0.23 (−1.67 to 4.69) IVART 3.55 (2.85–4.42) 0.21 (−2.20 to 4.90)
WNL 3.08 (2.64–3.59) 0.01 (−0.18 to 2.88) WNL 3.43 (2.71–4.35) 0.03 (−0.46 to 2.82)
Piperaquine (n = 31) NONMEM 3.17 (2.58–3.76) Piperaquine 
(n = 28)
NONMEM 3.80 (3.17–4.43)
GP 3.13 (2.54–3.85) 0.08 (−0.50 to 3.63) GP 3.88 (3.03–4.96) 0.02 (0.29 to 4.32)
ICE 3.21 (2.59–3.96) 0.21 (−0.07 to 3.63) ICE 4.13 (3.26–5.25) 0.26 (0.03 to 4.32)
IVART 3.07 (2.47–3.82) 0.20 (−2.59 to 4.60) IVART 4.06 (3.24–5.09) 0.26 (−0.92 to 4.32)
WNL 2.83 (2.37–3.37) 0.01 (−0.52 to 3.61) WNL 3.82 (3.01–4.86) −0.01 (−0.26 to 4.16)
Mefloquine (n = 31) NONMEM 2.48 (2.18–2.78) Mefloquine 
(n = 29)
NONMEM 2.96 (2.53–3.38)
GP 2.46 (2.10–2.89) 0.03 (−0.15 to 5.04) GP 3.11 (2.48–3.91) 0.01 (−0.23 to 5.07)
ICE 2.60 (2.24–3.02) 0.19 (0.01 to 5.04) ICE 3.25 (2.64–4.00) 0.18 (0.04 to 5.19)
IVART 2.38 (2.05–2.75) 0.08 (−0.86 to 0.92) IVART 3.04 (2.53–3.65) 0.19 (−1.63 to 5.19)
WNL 2.42 (2.08–2.83) 0.02 (−0.15 to 4.21) WNL 3.02 (2.41–3.78) −0.01 (−0.69 to 5.05)
Amodiaquine 
(n = 30)
NONMEM 4.43 (3.37–5.50) Amodiaquine 
(n = 28)
NONMEM 3.95 (3.26–4.65)
GP 3.68 (2.89–4.70) 0.06 (−0.37 to 4.67) GP 3.89 (3.03–4.98) 0.06 (−0.54 to 4.50)
ICE 4.01 (3.22–5.00) 0.24 (0.03 to 4.67) ICE 4.12 (3.28–5.18) 0.19 (−0.24 to 4.50)
IVART 4.01 (3.22–5.00) 0.24 (0.03 to 4.67) IVART 4.17 (3.33–5.24) 0.19 (−0.24 to 4.50)
WNL 3.64 (2.86–4.63) 0.05 (−0.43 to 3.67) WNL 3.87 (3.03–4.95) 0.02 (0.28 to 4.47)
Artesunate (n = 31) NONMEM 2.74 (2.38–3.10) Artesunate 
(n = 28)
NONMEM 2.74 (2.38–3.10)
GP 2.63 (2.19–3.15) −0.05 (−0.35 to 4.55) GP 3.67 (2.75–4.89) 0.18 (−0.54 to 4.79)
ICE 2.94 (2.49–3.46) 0.20 (0.35 to 4.55) ICE 3.92 (3.01–5.10) 0.24 (0.01 to 4.79)
IVART 3.03 (2.52–3.65) 0.32 (−0.68 to 7.12) IVART 3.84 (2.94–5.01) 0.18 (−0.38 to 4.38)
WNL 2.63 (2.19–3.15) −0.01 (−0.37 to 4.51) WNL 3.64 (2.76–4.79) 0.14 (−0.31 to 4.49)
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in parallel, but with a lower dynamic range, an approach 
more suited for anti-malarials for which the IC50 range is 
well defined.
High throughput analysis
The ability to perform multiple plate analysis provides 
significant advantages for high throughput processing of 
large numbers of samples and a range of different anti-
malarials. This feature is only available for IVART and 
GraphPad Prism 6.0.
Data processing time
Outputs from all programs can be obtained as an Excel 
worksheet (HN-NonLin), a csv file (ICE and IVART), pdf 
file (IVART), or can be exported to Word or Excel (Win-
Nonlin and GraphPad Prism 6.0). The process from raw data 
conversion until final outputs was timed for each package. 
Since some programs are capable of analysing multiple drug 
plates and/or isolates, timing was performed by running a 
single isolate for five drugs on two 96-well plates (=single 
run). A single run could be completed on average in 40  s 
with GraphPad Prism 6.0 since multiple drug plates can be 
analysed in parallel and the results are updated instantly 
when new data are entered. HN-NonLin took 45 s, with the 
delay attributable to data from different plates having to be 
entered separately. Results from IVART can be obtained in 
approximately 90 s because raw data need to be uploaded 
to, and results downloaded from a server. A single run for 
ICE took 4–5 min, the main reason being that response data 
need to be entered per drug and per isolate.
Offline capabilities
For investigators working in resource-limited field set-
tings with unreliable internet connection, the capability 
of offline data analysis has significant advantages. IVART 
and ICE require internet connection for uploading raw 
data to a server and calculations are generated online. 
WinNonlin, GraphPad Prism 6.0 and HN-NonLin allow 
offline data analysis.
Conclusions
The lack of standardized approaches to the analysis of 
in  vitro drug susceptibility continues to confound anti-
malarial resistance surveillance and comparison of data 
generated from different laboratories. Reassuringly, the 
current study demonstrates that the various statistical 
programs produce good overall concordance for IC50 
estimates across different drugs and for both Plasmodium 
species tested. However, there were some important dif-
ferences. In 5.4  % of drug assays, there were significant 
differences between approaches. In general, these were 
attributable to how the packages dealt with noisy data. 
Since serial dilutions of drug concentrations are almost 
universally adopted, the confidence of estimates for 
highly resistant isolates can be wide. No matter which 
analytical platform is used, these important isolates need 
to be individually scrutinized.
For routine and medium to high throughput drug 
susceptibility testing, GraphPad Prism 6.0 and IVART 
offered distinct advantages, including their capability to 
process multiple plates in parallel and the availability of 
all necessary output parameters to assess the accuracy 
of data modelling and hence, facilitate interpretation of 
the final data. For smaller scale drug testing, all statisti-
cal packages tested generated comparable IC50 estimates. 
Investigators working in remote areas with poorer infra-
structure, including limited internet connection, may 
prefer the freely available HN-NonLin for data analysis.
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